Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
Breast Cancer Res
; 22(1): 14, 2020 Jan 31.
Article
en En
| MEDLINE
| ID: mdl-32005287
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2020
Tipo del documento:
Article